Synonyms: AM-715 | Chibroxin® | MK-0366 | Noroxin®
norfloxacin is an approved drug (FDA (1986), EMA)
Compound class:
Synthetic organic
Comment: Norfloxacin is a fluoroquinolone compound with broad-spectrum antibacterial activity [3].
|
|
No information available. |
Summary of Clinical Use ![]() |
Norfloxacin has approval from the US FDA with a 'Boxed Warning' to highlight the risk of serious adverse reactions. An oral formulation (Noroxin®) and an ophthalmic solution (Chibroxin®) were marketed in the US by Merck but are now discontinued. The drug has EMA approval and is marketed in a number of European countries, however the EMA has issued restrictive guidelines on the use of fluoroquinolone containing medicines [2]. In 2008, the EMA withdrew authorisation for the use of oral formulations of norfloxacin to treat complicated pyelonephritis [1]. Other national approval agencies may have granted marketing authorisation. See Drugs.com's International Drug Names list for further information. |
External links ![]() |
For extended ADME data see the following: Drugs.com |